JP2019532052A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532052A5
JP2019532052A5 JP2019515428A JP2019515428A JP2019532052A5 JP 2019532052 A5 JP2019532052 A5 JP 2019532052A5 JP 2019515428 A JP2019515428 A JP 2019515428A JP 2019515428 A JP2019515428 A JP 2019515428A JP 2019532052 A5 JP2019532052 A5 JP 2019532052A5
Authority
JP
Japan
Prior art keywords
sulfonyl
pyrrolidine
hydroxymethyl
hydroxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515428A
Other languages
English (en)
Japanese (ja)
Other versions
JP7106528B2 (ja
JP2019532052A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055702 external-priority patent/WO2018055526A1/en
Publication of JP2019532052A publication Critical patent/JP2019532052A/ja
Publication of JP2019532052A5 publication Critical patent/JP2019532052A5/ja
Application granted granted Critical
Publication of JP7106528B2 publication Critical patent/JP7106528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515428A 2016-09-20 2017-09-20 Trpv4拮抗薬 Active JP7106528B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662397008P 2016-09-20 2016-09-20
US62/397,008 2016-09-20
US201762482300P 2017-04-06 2017-04-06
US62/482,300 2017-04-06
PCT/IB2017/055702 WO2018055526A1 (en) 2016-09-20 2017-09-20 Trpv4 antagonists

Publications (3)

Publication Number Publication Date
JP2019532052A JP2019532052A (ja) 2019-11-07
JP2019532052A5 true JP2019532052A5 (enExample) 2021-02-12
JP7106528B2 JP7106528B2 (ja) 2022-07-26

Family

ID=60084021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515428A Active JP7106528B2 (ja) 2016-09-20 2017-09-20 Trpv4拮抗薬

Country Status (10)

Country Link
US (1) US11260049B2 (enExample)
EP (1) EP3515888B1 (enExample)
JP (1) JP7106528B2 (enExample)
KR (1) KR20190049865A (enExample)
CN (1) CN109790116B (enExample)
AU (1) AU2017330620A1 (enExample)
CA (1) CA3036933A1 (enExample)
ES (1) ES2877763T3 (enExample)
RU (1) RU2019110821A (enExample)
WO (1) WO2018055526A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
TWI878266B (zh) 2019-02-15 2025-04-01 愛爾蘭商博士倫愛爾蘭有限公司 治療眼表痛之方法
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法
CA3180132A1 (en) 2020-04-30 2021-10-30 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN115776890A (zh) 2020-07-16 2023-03-10 拉夸里亚创药株式会社 作为眼病治疗剂的trpv4抑制剂
CN112500419A (zh) * 2020-11-23 2021-03-16 浙大城市学院 一种环氧稠合的2-亚甲基吡咯烷类化合物及其制备方法
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
PT77471B (en) 1982-10-08 1986-08-19 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
CA1272917A (en) 1985-07-30 1990-08-21 Paul Kenneth Rand Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
ES2201318T3 (es) 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
WO2003050154A2 (en) 2001-12-06 2003-06-19 Cornell Research Foundation, Inc. Catalytic carbonylation of three and four membered heterocycles
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP4969238B2 (ja) 2003-03-27 2012-07-04 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
PL1730676T3 (pl) 2004-02-16 2014-04-30 Glaxo Group Ltd Licznik do stosowania z dozownikiem leku
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
CN101103027A (zh) 2004-04-28 2008-01-09 默克公司 3,3-二取代四氢吡喃基环戊基酰胺趋化因子受体活性调节剂
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
CN1329374C (zh) 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
US20080064736A1 (en) 2004-07-12 2008-03-13 Bayer Cropscience Ag Substituted 2-Pyrrolidone Derivatives as Fungicides and Insecticides
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
AR058558A1 (es) 2005-12-21 2008-02-13 Schering Corp Derivados de anilina sustituida utiles como antagonistas de la histamina h3
US20090012011A1 (en) * 2006-01-11 2009-01-08 Smithkline Beecham Corporation Novel Compounds
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US20110046199A1 (en) 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
SG11201503556PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
EP2970121B1 (en) 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
AU2014230122A1 (en) 2013-03-15 2015-08-06 AbbVie Deutschland GmbH & Co. KG Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6272832B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑

Similar Documents

Publication Publication Date Title
JP2019532052A5 (enExample)
JP2019529443A5 (enExample)
JP2019532054A5 (enExample)
RU2019111882A (ru) Антагонисты trpv4
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
JP2018510857A5 (enExample)
JP2017511794A5 (enExample)
JP2013523710A5 (enExample)
JP2010518026A5 (enExample)
RU2015139590A (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
JP2016526576A5 (enExample)
RU2019110821A (ru) Антагонисты trpv4
JP7701473B2 (ja) Lpa受容体アンタゴニスト及びそれらの使用
JP6353530B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキサミド化合物
JP2017515844A5 (enExample)
JP2017125037A (ja) イミダゾピロリジノン化合物
JP2014500322A5 (enExample)
JP2020506171A5 (enExample)
JP2019505541A5 (enExample)
JP2008222557A (ja) ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物
AU2024202860A1 (en) Metalloenzyme inhibitor compounds
JP2013519724A5 (enExample)
RU2009133846A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2013523814A5 (enExample)
JP2017519023A5 (enExample)